

24 Lifesciences

**Intravenous Immunoglobulin (IVIg) Market
Regional Analysis, Demand Analysis and
Competitive Outlook 2025-2032**

•

Market Overview




Global Intravenous Immunoglobulin (IVIg) market size was valued at USD 10.02 billion in 2024. The market is projected to grow from USD 10.65 billion in 2025 to USD 15.3 billion by 2032, exhibiting a CAGR of 6.4% during the forecast period.

Intravenous Immunoglobulin (IVIg) is a purified antibody solution derived from pooled human plasma, containing concentrated immunoglobulins (primarily IgG) from thousands of healthy donors. This biologic therapy plays a critical role in immune modulation and replacement therapy, primarily used for treating immunodeficiency disorders, autoimmune diseases, and acute infections. The preparation involves complex fractionation and viral inactivation processes to ensure safety and efficacy.

Market size

MARKET INSIGHTS



2024

USD 10.02 billion in 2024

2032

USD 15.3 billion by 2032

CAGR

CAGR of 6.4%


<https://www.24lifesciences.com>

Segment Types

- **IVIg Liquid**
- **IVIg Powder**


Segment Application

- Immunodeficiency
- Autoimmune Disease
- Acute Infection
- Neurological Disorders



Our Key Players

- CSL Behring (U.S./Australia)
- Grifols, S.A. (Spain)
- Baxter International Inc. (U.S.)
- Octapharma AG (Switzerland)
- Biotest AG (Germany)
-



Regional Analysis

North America

North America dominates the global IVIg market, accounting for approximately 45% of total revenue share. The U.S. drives this growth due to high prevalence of immunodeficiency disorders, robust healthcare infrastructure, and favorable reimbursement policies. The FDA's stringent quality controls ensure product safety, while increasing off-label usage in neurological disorders expands market potential. However, pricing pressures from bulk procurement programs and limited plasma collection during COVID-19 created temporary supply constraints. Manufacturers are investing aggressively in plasma collection centers to meet the rising demand, particularly for chronic inflammatory demyelinating polyneuropathy (CIDP) treatment - which represents nearly 25% of U.S. IVIg utilization.

**"Exclusive Analysis Inside:
Download the [2025] Report Now"**

<https://www.24lifesciences.com/download-sample/1083/intravenous-immunoglobulin-ivig-market>



<https://www.24lifesciences.com>

Connect with us.



Email

help@24lifesciences.com



Call us

+91 9425150513 (Asia)



Contact Us
City Vista ,Kharadi

<https://www.24lifesciences.com>